Rigetti, D-Wave, or IonQ: Which Quantum Stock Has the Best Shot at Survival?

IonQ reported Q2 revenue of $80.1 million, up 287% year over year, and expects organic quantum-computing revenue to double this year, supported by $3.0 billion of cash. However, its adjusted EBITDA loss widened to $120.3 million from $36.5 million, while Rigetti generated only $5.1 million of revenue and D-Wave $3.1 million despite strong bookings growth. IonQ appears best positioned financially among the three quantum companies, but its 57x trailing price-to-sales multiple versus roughly 8x for the technology sector and the industry's unproven commercialization outlook imply substantial valuation and volatility risk.

Analysis

IONQ’s apparent commercial lead is less investable than the headline growth suggests because consolidated revenue now mixes a lower-multiple foundry business with quantum services. The key valuation question is therefore whether investors continue assigning a pure-play quantum multiple to acquired semiconductor revenue; any disclosure separating organic quantum ARR, gross margin, and bookings could trigger a sharp multiple reset. With a 57x trailing sales valuation, even sustained rapid growth is insufficient if cash burn remains above the pace of gross-profit formation.

RGTI and QBTS have a more acute financing-risk trade-off: nominal cash runway can support operations, but it does not protect equity holders from dilution if technical milestones slip and the market closes to speculative capital. Their small revenue bases also make quarterly percentage-growth figures statistically noisy, while a single contract delay can materially change sentiment. The more relevant competitive risk is that enterprise customers may use cloud access to multiple quantum modalities rather than standardize on either platform, limiting durable pricing power for all three vendors.

Near term, quantum remains a momentum/liquidity factor rather than an earnings factor, leaving crowded shorts vulnerable to retail-driven squeezes. Over 1-3 months, separate reporting of acquired versus organic revenue, bookings-to-revenue conversion, and EBITDA-loss trajectory are the catalysts that can differentiate IONQ from weaker peers. Over 6-18 months, the thesis is falsified positively only by repeatable commercial workloads producing expanding gross margins and materially lower cash burn, not additional research collaborations or bookings announcements.

The contrarian view is that IONQ may be the wrong short despite its valuation: its balance-sheet capacity can turn the current downturn in smaller quantum names into an acquisition opportunity, consolidating talent, IP, and customer channels before the category matures. That optionality argues for a relative-value expression rather than an outright bearish position, particularly if broader AI/compute enthusiasm remains strong.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long IONQ / short QBTS, sized beta-neutral. IONQ’s funding flexibility and broader revenue base should outperform if speculative capital tightens; exit if QBTS demonstrates two consecutive quarters of revenue conversion consistent with bookings or IONQ’s organic quantum revenue growth falls below management’s stated trajectory.
• For directional exposure, wait for IONQ’s next filing or earnings release before adding longs; require segment disclosure showing quantum revenue growth and stable/improving gross margin excluding acquired operations. If those metrics are absent, avoid chasing strength because valuation compression can dominate operational progress over the next 1-3 months.
• Use put spreads rather than naked shorts in RGTI or QBTS after momentum-driven rallies: target 3-6 month maturities and cap premium at 1% of portfolio NAV per name. The downside case is dilution or contract-conversion disappointment; invalidate on a verified large multi-year commercial contract with revenue recognition, not merely a partnership announcement.
• Monitor SKYT for post-transaction integration disclosures: if foundry revenue and margins prove resilient, it may provide a less volatile semiconductor-manufacturing exposure than quantum equities. Do not treat the transaction as automatically accretive until purchase accounting, customer concentration, and capital-expenditure requirements are disclosed.
• Keep HPE on watch rather than trade it on this development. Its quantum partnerships are strategically useful for HPC positioning but too small to affect consolidated earnings; a trade requires evidence of quantum-enabled systems sales entering backlog at a scale material to HPE guidance.